European credit markets are trading at a premium to the US for the first time in more than three years as investors have scooped up European corporate bonds and dumped US debt following a stark ...

Topline data were announced from a phase 3 trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

Shares of Hello Group Inc. MOMO -9.16% Get Free Report fell sharply during pre-market trading after reporting weak quarterly results. Hello Group posted fourth-quarter adjusted EPADS of 18 cents ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M.

The deal size was reduced to $175M from $250M and priced below last closing price of $14.30. BofA, Evercore ISI, Goldman Sachs, Stifel and ...

Said Azure CEO and Cofounder Ross Maguire, who accepted the award: "Of all of the awards we've achieved during our three ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

Samimy covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Mineralys Therapeutics, Inc., and Rani Therapeutics Holdings. ;'> Currently, the analyst ...

Mineralys Therapeutics plans $250M share offering after lorundrostat's Phase 3 success; Coherus cuts 30% staff; BioNTech's melanoma trial fails ...